Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2019
SIETES contiene 92854 citas

 
 
 1 a 20 de 397 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen

Se ha producido un error durante la generación de la página

. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103213]
2. Cita con resumen
Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]
3. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
4. Cita con resumen
Vaidya JS, Massarut S, Vaidya HJ, Alexander EC, Richards T, Caris JA, Sirohi B, Tobias JS. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018;360:j5913. [Ref.ID 102449]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ 2016;354:8 de octubre. [Ref.ID 100796]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Donneyong MM, Bykov K, Bosco-Levy P, Dong Y-H, Levin R, Gagne JJ. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ 2016;354:i5014. [Ref.ID 100795]
7. Cita con resumen
Anónimo. Anastrozole: syndromes du canal carpien. Prescrire 2016;36:426. [Ref.ID 100544]
8.Enlace a cita originalTiene citas relacionadas
Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy?. Lancet 2015;386:1317-9. [Ref.ID 99617]
9. Cita con resumen
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF, Austrian Breast, and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;386:433-43. [Ref.ID 99481]
10. Cita con resumen
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52. [Ref.ID 99276]
11. Cita con resumen
Chlebowski RT. IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol 2015;16:7-9. [Ref.ID 98773]
12.Enlace a cita original Cita con resumen
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, on behalf of the IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015;16:67-75. [Ref.ID 98772]
13. Cita con resumen
Yeo B, Turner NC, Jones A. Medical management of breast cancer. BMJ 2014;348:g3608. [Ref.ID 98044]
14.Tiene citas relacionadas
Hugo HS. Hormone theray in premenopausal women with early-stage breast cancer. N Engl J Med 2014;371:175-6. [Ref.ID 97810]
15.Tiene citas relacionadas Cita con resumen
Pagani O, Regan MM, Walley BA, Fleming GF, Collecni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Steams V, Bonnefoi HR, Martino S, Geyer Jr CE, Pinotti G, Puglisi F, Crivellari D, Rushtaller T, Winer EP, Rabaglio-Poretti M, Malbach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, for the TEXT and SOFT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18. [Ref.ID 97807]
16. Cita con resumen
Evans-Brown M, Kimergård A, McVeigh J, Chandler M, Brandt SD. Is tamoxifen being sold to bodybuilders?. BMJ 2014;348:g1476. [Ref.ID 97330]
17. Cita con resumen
Anónimo. Atteintes de la cornée d'origine médicamenteuse. Prescrire 2013;33:908-13. [Ref.ID 96721]
18.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Bonanni B, Constantino JP, Cummings S, Decensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data1827-1834. Lancet 2013;381:1827-34. [Ref.ID 95506]
19.Tiene citas relacionadas
Howell A, Evans DG. Breast cancer prevention: SERMs come of age. Lancet 2013;381:1795-7. [Ref.ID 95498]
20. Cita con resumen
Nelson HD, Smith MEB, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:604-14. [Ref.ID 95272]
Seleccionar todas
 
 1 a 20 de 397 siguiente >>